Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Lymphoma, Non-HodgkinMultiple Myeloma
Interventions
DRUG

G-CSF Plus Plerixafor

Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

Trial Locations (8)

Unknown

University of Arkansas for Medical Sciences, Little Rock

UCLA School of Medicine, Loa Angeles

Loyola University Medical Center, Maywood

University of Iowa, Iowa City

University of Minnesota, Minneapolis

Mayo Clinic, Rochester

Roswell Park Cancer Institute, Buffalo

Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AnorMED

INDUSTRY

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00322491 - Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter